.png)
Consumers who paid any amount of money for retail purchases of Vivimed Losartan finished drug formulations may be eligible to claim a cash payment from a class action settlement.
Vivimed Life Sciences Pvt Ltd. and Strides Pharma Science Ltd. agreed to pay $1,899,000 to settle a class action lawsuit. The lawsuit alleged Vivimed manufactured, distributed and/or sold Losartan medications contaminated with probable human carcinogens, specifically nitrosamines such as N-nitrosodimethylamine, resulting in economic losses to consumers.
The settlement is part of a larger multidistrict litigation, In re: Valsartan, Losartan and Irbesartan Products Liability Litigation. There is also a $2,000,000 Aurobindo Irbesartan settlement and a $11,365,489.80 Hetero Valsartan settlement.
Who can file a claim?
Individuals may file a claim if all of the following apply:
- They are an individual in the United States, its territories or possessions.
- They paid any amount of money for retail purchases of Vivimed Losartan finished drug formulations (not those made through third-party payors or government programs).
- The medication includes one of the following National Drug Codes:
- 23155-644-09
- 23155-644-10
- 23155-645-03
- 23155-645-09
- 23155-645-10
- 23155-646-03
- 23155-646-09
- 23155-646-10
Pharmacy benefit managers do not qualify for this settlement.
How much can class members get?
The settlement administrator will base payments to eligible class members on the quantity of qualifying Vivimed Losartan they purchased. The standard award is up to $4.30 for each 30-day supply of qualifying Vivimed Losartan purchased up to a maximum of $43.
However, consumers who provide documentation showing they paid more than $4.30 for a 30-day supply out of pocket may receive a payment above the $4.30 per 30-day supply and $43 total cap.
There is no cap for documented claims above the standard amount; however, the settlement caps total payments to consumers at 90% of the net settlement fund after deductions for attorneys’ fees, expenses, administration costs and service awards. If the total of all valid claims exceeds this cap, the settlement administrator will reduce payments proportionally.
How to claim a class action rebate
Class members can submit the online claim form or download, print and complete the PDF claim form and mail it to the settlement administrator. The claim deadline is June 2, 2026.
Settlement administrator's mailing address: Vivimed Settlement Notice Administrator, PO Box 3376, Baton Rouge, LA 70821
The settlement website does not specify payment options.
What proof or documentation is required to submit a claim?
- For claims up to $4.30 per 30-day supply and $43 total, class members do not need to submit documentation. However, the settlement administrator may request proof to verify claims.
- For claims above $4.30 per 30-day supply or above $43 total, class members must submit documentation, such as pharmacy receipts or records.
$1.9 million settlement fund
The $1,899,000 settlement fund includes:
- Settlement administration costs: To be determined
- Attorneys' fees: Up to $633,000
- Attorneys' expenses: To be determined
- Service awards to class representatives: $1,000 for the consumer plaintiff and $3,000 each for the two TPP representative plaintiffs ($7,000 total)
- Payments to class members: Remaining funds
Important dates
- Deadline to file a claim: June 2, 2026
- Exclusion deadline: June 2, 2026
- Fairness hearing: June 30, 2026
When is the Vivimed Losartan settlement payout date?
The settlement administrator will distribute payments after the court resolves any appeals and grants final approval of the settlement.
Why is there a class action settlement?
The class action lawsuit alleged Vivimed manufactured and sold Losartan medications containing nitrosamine impurities, specifically NMBA, which are probable human carcinogens. The plaintiffs claimed these impurities caused economic losses to consumers who purchased the affected medications.
Vivimed denied any wrongdoing, but the parties agreed to settle to avoid the uncertainty and expense of further litigation.
.webp)
.webp)
.webp)
.webp)
.webp)
.webp)
.webp)
.svg)